加载中
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
NASDAQHealthcareMedical - Healthcare Information Services
最新数据
US$67.7671
−US$2.5829 · -3.67%
常规交易时段
US$67.61
−US$2.74 · -3.89%
盘中时间采用ET。市场数据可能有所延迟。
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
日内区间
当前US$67.61
52周区间
当前US$67.61
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 12.72亿 USD | 6.93亿 USD | 5.32亿 USD | 3.21亿 USD | 2.58亿 USD |
| 销货成本 | 4.74亿 USD | 3.12亿 USD | 2.46亿 USD | 1.9亿 USD | 1.74亿 USD |
| 毛利 | 7.98亿 USD | 3.81亿 USD | 2.86亿 USD | 1.3亿 USD | 8364.4万 USD |
| 研究与开发 | 3.19亿 USD | 3.17亿 USD | 1.85亿 USD | 1.62亿 USD | 1.28亿 USD |
| 销售、一般及管理费用 | 7.15亿 USD | 7.55亿 USD | 2.97亿 USD | 2.33亿 USD | 1.99亿 USD |
| 营业费用 | 10.51亿 USD | 10.72亿 USD | 4.82亿 USD | 3.96亿 USD | 3.27亿 USD |
| 利息收入 | 1262.8万 USD | 1108.4万 USD | 760.1万 USD | 303.2万 USD | 62.3万 USD |
| 利息支出 | 7026.7万 USD | 5365.3万 USD | 4686.9万 USD | 2189.4万 USD | 1518.4万 USD |
| 折旧和摊销 | 1.02亿 USD | 3724.5万 USD | 3333.2万 USD | 3041万 USD | 2388.1万 USD |
| 营业利润 | −2.53亿 USD | −6.91亿 USD | −1.96亿 USD | −2.65亿 USD | −2.44亿 USD |
| 净利润 | −2.45亿 USD | −7.06亿 USD | −2.14亿 USD | −2.9亿 USD | −2.59亿 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$72.60
上涨空间 7.38%报告持有此股票敞口的交易所交易基金。
ARK Innovation ETFARKK5.65亿5.10%55.62亿 USD0.75%US$87.52-0.88%
Vanguard Morningstar Total Stock Market ETFVTI2.28亿0.01%2.3万亿 USD0.03%US$379.54-0.39%
ARK Genomic Revolution ETFARKG1.76亿8.33%15.57亿 USD0.75%US$48.55-3.17%
Vanguard Morningstar Small-Cap ETFVB1.65亿0.09%1853亿 USD0.03%US$285.2-0.62%
Vanguard Morningstar Small-Cap Growth ETFVBK9447.17万0.21%447亿 USD0.05%US$338.87-0.98%
Vanguard Extended Market ETFVXF7549.6万0.08%954亿 USD0.05%US$231.53-0.84%
iShares Biotechnology ETFIBB5729.97万0.55%104.01亿 USD0.44%US$197.29-2.98%
JPMorgan U.S. Tech Leaders ETFJTEK5600.66万1.15%48.78亿 USD0.65%US$106.69-0.68%ARK Innovation ETFARKKVanguard Morningstar Total Stock Market ETFVTIARK Genomic Revolution ETFARKGVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBJPMorgan U.S. Tech Leaders ETFJTEKAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
